Abstract
We use recent data and research results to approximate the probability that an air traveler in coach will contract Covid-19 on a US domestic flight two hours long, both when all coach seats are full and when all but middle seats are full. The point estimates we reach based on data from late June 2020 are 1 in 4,300 for full flights and 1 in 7,700 when middle seats are kept empty. These estimates are subject to both quantifiable and nonquantifiable sources of uncertainty, and sustain known margins of error of a factor about 2.5. However, because uncertainties in key parameters affect both risk estimates the same way, they leave the relative risk ratio for “fill all seats” compared to “middle seat open” close to 1.8 (i.e., close to 1/4,300)/(1/7,700). We estimate the mortality risks caused by Covid-19 infections contracted on airplanes, taking into account that infected passengers can in turn infect others. The point estimates—which use 2019 data about the percentage of seats actually occupied on US flights--range from one death per 400,000 passengers to one death per 600,000. These death-risk levels are considerably higher than those associated with plane crashes but comparable to those arising from two hours of everyday activities during the pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No such body has considered the work.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.